SynCardia Facebook SynCardia Twitter SynCardia LInkedIn SynCardia Google Plus SynCardia Youtube

SynCardia Systems, Inc.

Press Release:

Dr. Marvin Slepian Publishes 8-Page Article on SynCardia's Total Artificial Heart in U.S. Cardiology

SynCardia Chairman Also Publishes Articles in Nature Materials, Journal of the American Dental Association

Marvin J. Slepian, MD, SynCardia Chairman and Chief Scientific Officer, Professor of Medicine (Cardiology and Biomedical Engineering) at the University of Arizona Marvin J. Slepian, MD, SynCardia Chairman and Chief Scientific Officer, Professor of Medicine (Cardiology and Biomedical Engineering) at the University of Arizona TUCSON, Ariz. – March 31, 2011 – SynCardia Systems, Inc. announced today that the company's Chairman and Chief Scientific Officer, Marvin J. Slepian, MD, has published an eight-page article in the spring issue of U.S. Cardiology, titled "The SynCardia Temporary Total Artificial Heart—Evolving Clinical Role and Future Status."

"The SynCardia Temporary Total Artificial Heart (TAH) is the only clinically effective, Conformité Européene (CE) registered, Food and Drug Administration (FDA) approved and Centers for Medicare and Medicaid Services (CMS) reimbursed total artificial heart system available in the world today," wrote Dr. Slepian, Professor of Medicine (Cardiology and Biomedical Engineering) at the University of Arizona. "...The TAH offers several advantages relative to present continuous flow left ventricular assist devices (LVADs), including higher 'quality' flow rates, reduced afterload and preload sensitivity, reduced thrombosis and stroke rates, and freedom from device-induced bleeding."

Also this month, an article Dr. Slepian co-authored, titled "Materials for multifunctional balloon catheters with capabilities in cardiac electrophysiological mapping and ablation therapy" was published in Nature Materials. The article discusses using materials that integrate directly with the thin elastic membranes of otherwise conventional balloon catheters to provide diverse, multimodal functionality suitable for clinical use.

Similar to a heart transplant, SynCardia’s Total Artificial Heart replaces both failing ventricles and the four native valves.

Dr. Slepian also co-authored an article published in the Journal of the American Dental Association this month, titled "The effect of subantimicrobial-dose–doxycycline periodontal therapy on serum biomarkers of systemic inflammation." The article discusses using subantimicrobial-dose–doxycycline (SDD) as an adjunct to periodontal maintenance therapy to help reduce systemic measures of inflammation associated with both periodontitis and coronary artery disease (CAD).

On March 8, for the second year in a row, Dr. Slepian presented on SynCardia's Total Artificial Heart at the 2nd Annual Medical Devices Summit in Boston, MA.

###

About SynCardia Systems, LLC
SynCardia Systems, LLC in Tucson, Ariz., is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. For people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure), the SynCardia temporary Total Artificial Heart is used as a bridge to transplant, helping them survive until a matching donor heart becomes available. SynCardia also manufactures the Freedom® portable driver, which powers the SynCardia Total Artificial Heart and allows clinically stable patients to be discharged from the hospital to enjoy life at home while they wait for a heart transplant.

Follow SynCardia: Facebook | Twitter | LinkedIn | Google+

SynCardia Contact:
Janelle Drumwright, jdrumwright@syncardia.com, (520) 547-7463

Search offcanvas